KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Treasury Shares (2018 - 2025)

Alnylam Pharmaceuticals' Treasury Shares history spans 13 years, with the latest figure at $779000.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 54.84% year-over-year to $779000.0; the TTM value through Dec 2025 reached $779000.0, down 54.84%, while the annual FY2025 figure was $779000.0, 54.84% down from the prior year.
  • Treasury Shares reached $779000.0 in Q4 2025 per ALNY's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $1.7 million in Q4 2024 to a low of $292000.0 in Q4 2022.
  • Average Treasury Shares over 5 years is $993000.0, with a median of $1.0 million recorded in 2023.
  • Peak YoY movement for Treasury Shares: skyrocketed 870.94% in 2021, then tumbled 74.3% in 2022.
  • A 5-year view of Treasury Shares shows it stood at $1.1 million in 2021, then crashed by 74.3% to $292000.0 in 2022, then soared by 253.77% to $1.0 million in 2023, then soared by 66.99% to $1.7 million in 2024, then plummeted by 54.84% to $779000.0 in 2025.
  • Per Business Quant, the three most recent readings for ALNY's Treasury Shares are $779000.0 (Q4 2025), $1.7 million (Q4 2024), and $1.0 million (Q4 2023).